Novel pyrimidine Schiff bases and their selenium-containing nanoparticles as dual inhibitors of CDK1 and tubulin polymerase: design, synthesis, anti-proliferative evaluation, and molecular modelling

References

• Xu J-J, Zhang W-C, Guo Y-W, Chen X-Y, Zhang Y-N. Metal nanoparticles as a promising technology in targeted cancer treatment. Drug Deliv. 2022;29(1):664–678.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang L, Hei R, Li X, Cai H, Wu X, Zheng Q, Cai C. CDK inhibitors in cancer therapy, an overview of recent development. Am J Cancer Res. 2021;11(5):1913.
   PubMed Web of Science ®Google Scholar
• Yang B, Quan Y, Zhao W, Ji Y, Yang X, Li J, Li Y, Liu X, Wang Y, Li Y, et al. Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl) amino)-pyrrolo [2,3-d] pyrimidine derivatives as CDK inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):2169282.
   PubMed Web of Science ®Google Scholar
• Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–146.
   PubMed Web of Science ®Google Scholar
• Wu L, Qu X. Cancer biomarker detection: recent achievements and challenges. Chem Soc Rev. 2015;44(10):2963–2997.
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115.
   PubMed Web of Science ®Google Scholar
• Zhang XH, Hsiang J, Rosen ST. Flavopiridol (Alvocidib), a cyclin-dependent kinases (CDKs) inhibitor, found synergy effects with niclosamide in cutaneous t-cell lymphoma. J Clin Haematol. 2021;2(2):48.
   PubMedGoogle Scholar
• Cho YS, Angove H, Brain C, Chen CH-T, Cheng H, Cheng R, Chopra R, Chung K, Congreve M, Dagostin C, et al. Fragment-based discovery of 7-azabenzimidazoles as potent, highly selective, and orally active CDK4/6 inhibitors. ACS Med Chem Lett. 2012;3(6):445–449.
   PubMed Web of Science ®Google Scholar
• Freeman-Cook KD, Hoffman RL, Behenna DC, Boras B, Carelli J, Diehl W, Ferre RA, He Y-A, Hui A, Huang B, et al. Discovery of PF-06873600, a CDK2/4/6 inhibitor for the treatment of cancer. J Med Chem. 2021;64(13):9056–9077.
   PubMed Web of Science ®Google Scholar
• Saqub H, Proetsch-Gugerbauer H, Bezrookove V, Nosrati M, Vaquero EM, de Semir D, Ice RJ, McAllister S, Soroceanu L, Kashani-Sabet M, et al. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Sci Rep. 2020;10(1):1–13.
   PubMed Web of Science ®Google Scholar
• Cicenas J, Kalyan K, Sorokinas A, Stankunas E, Levy J, Meskinyte I, Stankevicius V, Kaupinis A, Valius M. Roscovitine in cancer and other diseases. Ann Transl Med. 2015;3(10):135–147.
   PubMed Web of Science ®Google Scholar
• Dai Y, Dent P, Grant S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor. Cell Cycle. 2002;1(2):128–137.
   Web of Science ®Google Scholar
• Tadesse S, Zhu G, Mekonnen LB, Lenjisa JL, Yu M, Brown MP, Wang S. A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl) pyrimidin-2-amines as highly potent CDK4/6 inhibitors. Future Med Chem. 2017;9(13):1495–1506.
   PubMed Web of Science ®Google Scholar
• Sorf A, Novotna E, Hofman J, Morell A, Staud F, Wsol V, Ceckova M. Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: interaction with carbonyl-reducing enzymes and ABC transporters. Biochem Pharmacol. 2019;163:290–298.
   PubMed Web of Science ®Google Scholar
• Mesguiche V, Parsons RJ, Arris CE, Bentley J, Boyle FT, Curtin NJ, Davies TG, Endicott JA, Gibson AE, Golding BT, et al. 4-Alkoxy-2, 6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003;13(2):217–222.
   PubMed Web of Science ®Google Scholar
• Lafanechère L. The microtubule cytoskeleton: an old validated target for novel therapeutic drugs. Front Pharmacol. 2022;13:3888.
   Web of Science ®Google Scholar
• Serpico AF, Febbraro F, Pisauro C, Grieco D. Compartmentalized control of Cdk1 drives mitotic spindle assembly. Cell Reports. 2022;38(4):110305.
   PubMed Web of Science ®Google Scholar
• Gigant B, Wang C, Ravelli RBG, Roussi F, Steinmetz MO, Curmi PA, Sobel A, Knossow M. Structural basis for the regulation of tubulin by vinblastine. Nature. 2005;435(7041):519–522.
   PubMed Web of Science ®Google Scholar
• Prota AE, Bargsten K, Diaz JF, Marsh M, Cuevas C, Liniger M, Neuhaus C, Andreu JM, Altmann K-H, Steinmetz MO, et al. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs. Proc Natl Acad Sci U S A. 2014;111(38):13817–13821.
   PubMed Web of Science ®Google Scholar
• Prota AE, Bargsten K, Northcote PT, Marsh M, Altmann K-H, Miller JH, Díaz JF, Steinmetz MO. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew Chem Int Ed Engl. 2014;53(6):1621–1625.
   PubMed Web of Science ®Google Scholar
• Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, Knossow M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004;428(6979):198–202.
   PubMed Web of Science ®Google Scholar
• Dorléans A, Gigant B, Ravelli RBG, Mailliet P, Mikol V, Knossow M. Variations in the colchicine-binding domain provide insight into the structural switch of tubulin. Proc Natl Acad Sci U S A. 2009;106(33):13775–13779.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang H, Gigant B, Yu Y, Wu Y, Chen X, Lai Q, Yang Z, Chen Q, Yang J, et al. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery. FEBS J. 2016;283(1):102–111.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Grimm S, Phuphanich S, Recht L, Zhu JZ, Kim L, Rosenfeld S, Fadul CE, Brain Tumor Investigational Consortium (BTIC). A phase 2 trial of verubulin for recurrent glioblastoma: a prospective study by the Brain Tumor Investigational Consortium (BTIC). J Neurooncol. 2014;118(2):335–343.
   PubMed Web of Science ®Google Scholar
• Siddiqui-Jain A, Hoj JP, Cescon DW, Hansen MD. Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization. Bioorg Med Chem Lett. 2018;28(5):934–941.
   PubMed Web of Science ®Google Scholar
• Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012;29(11):2943–2971.
   PubMed Web of Science ®Google Scholar
• McLoughlin EC, O’Boyle NM. Colchicine-binding site inhibitors from chemistry to clinic: a review. Pharmaceuticals. 2020;13(1):8.
   Web of Science ®Google Scholar
• Ferro C, Florindo HF, Santos HA. Selenium nanoparticles for biomedical applications: from development and characterization to therapeutics. Adv Healthcare Mater. 2021;10(16):2100598.
   Web of Science ®Google Scholar
• Ikram M, Javed B, Raja NI, Mashwani Z-u-R. Biomedical potential of plant-based selenium nanoparticles: a comprehensive review on therapeutic and mechanistic aspects. Int J Nanomed. 2021;16:249–268.
   PubMed Web of Science ®Google Scholar
• Singh KR, Nayak V, Singh J, Singh AK, Singh RP. Potentialities of bioinspired metal and metal oxide nanoparticles in biomedical sciences. RSC Adv. 2021;11(40):24722–24746.
   PubMed Web of Science ®Google Scholar
• Chen G, Yang F, Fan S, Jin H, Liao K, Li X, Liu G-B, Liang J, Zhang J, Xu J-F, et al. Immunomodulatory roles of selenium nanoparticles: novel arts for potential immunotherapy strategy development. Front Immunol. 2022;13:3939.
   Web of Science ®Google Scholar
• Liao G, Tang J, Wang D, Zuo H, Zhang Q, Liu Y, Xiong H. Selenium nanoparticles (SeNPs) have potent antitumor activity against prostate cancer cells through the upregulation of miR-16. World J Surg Onc. 2020;18(1):11.
   PubMed Web of Science ®Google Scholar
• Tian J, Wei X, Zhang W, Xu A. Effects of selenium nanoparticles combined with radiotherapy on lung cancer cells. Front Bioeng Biotechnol. 2020;8:598997.
   PubMed Web of Science ®Google Scholar
• Al-Otaibi AM, Al-Gebaly AS, Almeer R, Albasher G, Al-Qahtani WS, Abdel Moneim AE. Potential of green-synthesized selenium nanoparticles using apigenin in human breast cancer MCF-7 cells. Environ Sci Pollut Res Int. 2022;29(31):47539–47548.
   PubMed Web of Science ®Google Scholar
• Nayak V, Singh KR, Singh AK, Singh RP. Potentialities of selenium nanoparticles in biomedical science. New J Chem. 2021;45(6):2849–2878.
   Web of Science ®Google Scholar
• Ehudin MA, Golla U, Trivedi D, Potlakayala SD, Rudrabhatla SV, Desai D, Dovat S, Claxton D, Sharma A. Therapeutic benefits of selenium in hematological malignancies. Int J Mol Sci. 2022;23(14):7972.
   PubMed Web of Science ®Google Scholar
• Kumar A, Prasad KS. Role of nano-selenium in health and environment. J Biotechnol. 2021;325:152–163.
   PubMed Web of Science ®Google Scholar
• Alavi M, Rai M, Martinez F, Kahrizi D, Khan H, Rose Alencar de Menezes I, Douglas Melo Coutinho H, Costa J. The efficiency of metal, metal oxide, and metalloid nanoparticles against cancer cells and bacterial pathogens: different mechanisms of action. Cell Mol Biomed Rep. 2022;2(1):10–21.
   Google Scholar
• Kuršvietienė L, Mongirdienė A, Bernatonienė J, Šulinskienė J, Stanevičienė I. Selenium anticancer properties and impact on cellular redox status. Antioxidants. 2020;9(1):80.
   Web of Science ®Google Scholar
• Nogueira CW, Barbosa NV, Rocha JB. Toxicology and pharmacology of synthetic organoselenium compounds: an update. Arch Toxicol. 2021;95(4):1179–1226.
   PubMed Web of Science ®Google Scholar
• El-Kalyoubi S, Agili F, Adel I, Tantawy MA. Novel uracil derivatives depicted potential anticancer agents: in vitro, molecular docking, and ADME study. Arab J Chem. 2022;15(4):103669.
   Web of Science ®Google Scholar
• El-Kalyoubi S, Agili F, Zordok WA, El-Sayed ASA. Synthesis, in silico prediction and in vitro evaluation of antimicrobial activity, DFT calculation and theoretical investigation of novel xanthines and uracil containing imidazolone derivatives. Int J Mol Sci. 2021;22(20):10979.
   PubMed Web of Science ®Google Scholar
• El-Kalyoubi S, Agili F. Synthesis, in silico prediction and in vitro evaluation of antitumor activities of novel pyrido [2, 3-d] pyrimidine, xanthine and lumazine derivatives. Molecules. 2020;25(21):5205.
   PubMed Web of Science ®Google Scholar
• El-Kalyoubi SA, Taher ES, Ibrahim TS, El-Behairy MF, Al-Mahmoudy AMM. Uracil as a Zn-binding bioisostere of the allergic benzenesulfonamide in the design of quinoline–uracil hybrids as anticancer carbonic anhydrase inhibitors. Pharmaceuticals. 2022;15(5):494.
   Web of Science ®Google Scholar
• El-Kalyoubi S, El-Sebaey SA, Rashad AM, Al-Ghulikah HA, Ghorab MM, Elfeky SM. Synthesis, DFT calculations, and anti-proliferative evaluation of pyrimidine and selenadiazolopyrimidine derivatives as dual Topoisomerase II and HSP90 inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):2198163.
   PubMed Web of Science ®Google Scholar
• El-Kalyoubi S, Elbaramawi SS, Zordok WA, Malebari AM, Safo MK, Ibrahim TS, Taher ES. Design and synthesis of uracil/thiouracil based quinoline scaffolds as topoisomerases I&II inhibitors for chemotherapy: a new hybrid navigator with DFT calculation. Bioorg Chem. 2023;136:106560.
   PubMed Web of Science ®Google Scholar
• Kapur M, Soni K, Kohli K. Green synthesis of selenium nanoparticles from broccoli, characterization, application and toxicity. Adv Tech Biol Med. 2017;05(01):2379–1764.
   Google Scholar
• Wadhwani SA, Gorain M, Banerjee P, Shedbalkar UU, Singh R, Kundu GC, Chopade BA. Green synthesis of selenium nanoparticles using Acinetobacter sp. SW30: optimization, characterization and its anticancer activity in breast cancer cells. Int J Nanomed. 2017;12:6841–6855.
   PubMed Web of Science ®Google Scholar
• Ranjitha V, Ravishankar V. Extracellular synthesis of selenium nanoparticles from an actinomycetes streptomyces griseoruber and evaluation of its cytotoxicity on HT-29 cell line. Pharm Nanotechnol. 2018;6(1):61–68.
   PubMedGoogle Scholar
• Khalil A, Hassan ML, Ward AA. Novel nanofibrillated cellulose/polyvinylpyrrolidone/silver nanoparticles films with electrical conductivity properties. Carbohydr Polym. 2017;157:503–511.
   PubMed Web of Science ®Google Scholar
• Khalil AM, Georgiadou V, Guerrouache M, Mahouche-Chergui S, Dendrinou-Samara C, Chehimi MM, Carbonnier B. Gold-decorated polymeric monoliths: in-situ vs ex-situ immobilization strategies and flow through catalytic applications towards nitrophenols reduction. Polymer. 2015;77:218–226.
   Web of Science ®Google Scholar
• Fan W, Yan W, Xu Z, Ni H. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces. 2012;90:21–27.
   PubMed Web of Science ®Google Scholar
• Iqbal MS, Abbas K, Qadir MI. Synthesis, characterization and evaluation of biological properties of selenium nanoparticles from Solanum lycopersicum. Arab J Chem. 2022;15(7):103901.
   Web of Science ®Google Scholar
• Ashrafpour S, Moghadam TT. Interaction of silver nanoparticles with lysozyme: functional and structural investigations. Surf Interfaces. 2018;10:216–221.
   Web of Science ®Google Scholar
• Barnum KJ, O’Connell MJ. Cell cycle regulation by checkpoints. Cell Cycle Control Mech Protocols. 2014;1170:29–40.
   Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153–166.
   PubMed Web of Science ®Google Scholar
• Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140(15):3079–3093.
   PubMed Web of Science ®Google Scholar
• Wood DJ, Korolchuk S, Tatum NJ, Wang L-Z, Endicott JA, Noble MEM, Martin MP. Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition. Cell Chem Biol. 2019;26(1):121.e5–130.e5.
   Web of Science ®Google Scholar
• Kavallaris M. Erratum: microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(4):309–309.
   Web of Science ®Google Scholar
• Hammond JW, Cai D, Verhey KJ. Tubulin modifications and their cellular functions. Curr Opin Cell Biol. 2008;20(1):71–76.
   PubMed Web of Science ®Google Scholar
• Nam N-H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem. 2003;10(17):1697–1722.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya B, Panda D, Gupta S, Banerjee M. Anti‐mitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev. 2008;28(1):155–183.
   PubMed Web of Science ®Google Scholar
• Gaspari R, Prota AE, Bargsten K, Cavalli A, Steinmetz MO. Structural basis of cis-and trans-combretastatin binding to tubulin. Chem. 2017;2(1):102–113.
   Web of Science ®Google Scholar
• van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Langenhuijsen MM. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods. 1994;174(1-2):311–320.
   PubMed Web of Science ®Google Scholar
• Tahir SK, Kovar P, Rosenberg SH, Ng SC. Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. Biotechniques. 2000;29(1):156–160.
   PubMed Web of Science ®Google Scholar
• El-Zoghbi MS, El-Sebaey SA, Al-Ghulikah HA, Sobh EA. Design, synthesis, docking, and anticancer evaluations of new thiazolo [3, 2-a] pyrimidines as topoisomerase II inhibitors. J Enzyme Inhib Med Chem. 2023;38(1):2175209.
   PubMed Web of Science ®Google Scholar
• Al-Ghulikah HA, El-Sebaey SA, Bass AKA, El-Zoghbi MS. New pyrimidine-5-carbonitriles as COX-2 inhibitors: design, synthesis, anticancer screening, molecular docking, and in silico ADME profile studies. Molecules. 2022;27(21):7485.
   PubMed Web of Science ®Google Scholar
• Elfeky SM, Almehmadi SJ, Tawfik SS. Synthesis, in-silico, and in-vitro study of novel chloro methylquinazolinones as PI3K-δ inhibitors, cytotoxic agents. Arab J Chem. 2022;15(2):103614.
   Web of Science ®Google Scholar